Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Gopal, Ajay K.; Bartlett, Nancy L.; Forero‐Torres, Andres; Younes, Anas; Chen, Robert; Friedberg, Jonathan W.; Matous, Jeffrey; Shustov, Andrei R.; Smith, Scott E.; Zain, Jasmine; O’Meara, Megan M.; Fanale, Michelle A.

doi:10.3109/10428194.2013.876496

Cited by 45 publications

(29 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20,21 A retrospective analysis of elderly patients .60 years of age confirmed objective response rates of 56% in Hodgkin lymphoma and 100% in systemic ALCL, suggesting that the use of brentuximab vedotin as a single agent in these diseases in elderly patients may be a feasible option, even as initial treatment. 21 This is being tested in an ongoing trial of single-agent brentuximab vedotin in patients age $60 years with newly diagnosed Hodgkin lymphoma, and compelling antitumor activity has been demonstrated. At the time of an interim analysis of 13 patients, a response rate of 82% was reported in this historically challenging population of patients.…”

Section: Single Agent Resultsmentioning

confidence: 98%

Brentuximab vedotin

Ansell

2014

Blood

View full text Add to dashboard Cite

Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30(+) malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.

show abstract

Section: Single Agent Resultsmentioning

confidence: 98%

Brentuximab vedotin

Ansell

2014

Blood

View full text Add to dashboard Cite

show abstract

“…The median durations of overall response and CR were 12.6 and 13.2 months, respectively [8••]. In older adults (>60 year) with ALCL (and HL) BV has similar high response rates (100 % ORR in ALCL) with a very modest increase in adverse events [9]. Thus, single agent BV is effective and well-tolerated in older patients with PTCLs.…”

Section: Brentuximab-vedotinmentioning

confidence: 94%

Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

Hebb

Kohrt

2015

Curr Hematol Malig Rep

View full text Add to dashboard Cite

The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in their structure, targets, and mechanisms of action. Common mechanisms of action include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis, blocking of receptors or signaling pathways, delivery of cytotoxic agents to tumor cells, and binding to and blocking biologically active molecules. This review will focus on recent published evidence for the various MAbs used in the treatment of PTCLs. The results overall have been very promising, and the future will see more trials with these antibodies alone and in various therapy combinations, as well as newer ones with novel modifications, conjugates, and targets.

show abstract

“…74 A retrospective analysis of the safety and efficacy of BV compared safety data for older (≥60 years, median age 66) and younger patients (<60 years, median age 32) with relapsed CD30+ lymphomas. 75 Higher rates of anaemia (30 % versus 10 %), peripheral sensory neuropathy (60 % versus 46 %), fatigue (58 % versus 43 %) and AEs more than or equal to grade 3 (70 % versus 56 %) were reported in older patients, but the authors concluded that with appropriate monitoring, BV could be a useful treatment option for older patients with relapsed CD30+ lymphomas. In the study investigating retreatment with BV, the reported AEs were similar in type and frequency to those observed in the BV pivotal trials, with the exception of PN, which was observed in 69 % of patients; however, almost half (48 %) of the patients had pre-existing PN at baseline.…”

Section: Safety and Tolerability Of Brentuximab Vedotinmentioning

confidence: 98%

Antibody–Drug Conjugates in Relapsed/Refractory CD30-positive Lymphomas

Jäger¹,

Hutchings²

2015

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

Although chemotherapy and radiotherapy are associated with good outcomes in patients with advanced Hodgkin's lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), there is a need for alternative approaches to maximise control of the lymphoma in refractory and relapsed cases. Antibody-drug conjugates (ADCs) allow specific targeting of drugs to neoplastic cells. The ADC brentuximab vedotin (BV) has the ability to target cluster of differentiation (CD) 30+ tumour cells and initiate cytotoxic effects. In two phase II trials, BV resulted in objective responses in 75 % and 86 % of patients with refractory or relapsed HL and sALCL, respectively, with an acceptable toxicity profile. Based on these data, BV was granted accelerated approval by the US Food and Drug Administration for the treatment of refractory and relapsed HL and ALCL. A promising indication for BV is acting as a bridge to stem cell transplantation (SCT). Numerous studies are currently examining the role of BV as salvage therapy prior to autologous or allogeneic SCT, as well as in other clinical settings. KeywordsAntibody-drug conjugates, brentuximab vedotin, Hodgkin's lymphoma, systemic anaplastic large cell lymphoma Disclosure: Ulrich Jager has received honoraria and participated in Advisory Boards for Takeda. Martin Hutchings has participated in Advisory Boards for Celgene, Genentech, Janssen and Takeda, and has been a consultant to Genentech and Takeda. Support:The publication of this article was supported by Takeda, who were given the opportunity to review the article for scientific accuracy before submission. Any resulting changes were made at the author's discretion. Antibody-Drug Conjugates inRelapsed/Refractory CD30-positive Lymphomas This review will focus on the unmet needs in the management of HL and sALCL and discuss clinical studies investigating the efficacy and safety of BV. Current Standard of Care in Hodgkin's Lymphoma and Systemic Anaplastic Large Cell LymphomaHL is characterised by the orderly spread of disease from one lymph node to the other. Systemic symptoms are associated with advanced disease. The incidence of HL shows a bimodal age distribution, with the first peak in incidence rates in young adults, and the second peak in older people. 5 It is the most common malignancy in adolescents. 6 Despite the fact that first-line combined chemotherapy regimens, including doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD), achieve durable remission rates in approximately 80 % of cases, 7 a substantial proportion of patients with advanced HL (20-30 %) are refractory to therapy or relapse after initial treatment. 8 Remission rates can be increased by around 10 % with the use of more intensive chemotherapy regimens such as bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP), but this treatment carries the risk of serious adverse events (AEs). 9,10

show abstract

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Cited by 45 publications

References 29 publications

Brentuximab vedotin

Brentuximab vedotin

Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

Antibody–Drug Conjugates in Relapsed/Refractory CD30-positive Lymphomas

Contact Info

Product

Resources

About